Biomarkers for the early stages of clinical development in Alzheimer's disease;Biomarqueurs aux phases précoces de développement dans la maladie d'Alzheimer

Therapie

Volumn 65, Issue 4, 2010, Pages 285-

  Bordet, Régis ^a   Dartigues, Jean François ^b   Dubois, Bruno ^c   Goehrs, Jean Marie ^d   Vernoux, Laura ^e   Semah, Franck ^f   Pasquier, Florence ^f   Bidaut Mazel, Claude ^g  

^a UNIV LILLE   (France)

^b INSERM   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d SORBONNE UNIVERSITÉ   (France)

^e Innogenetics   (France)

^f LILLE UNIVERSITY HOSPITAL   (France)

^g GLAXOSMITHKLINE   (France)

Author keywords

Alzheimer's disease; Biomarker; Clinical development; Imaging

Indexed keywords

BIOLOGICAL MARKER; NOOTROPIC AGENT;

ALZHEIMER DISEASE; CLINICAL TRIAL; DEMENTIA; DIAGNOSTIC IMAGING; DRUG RESEARCH; DRUG SCREENING; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; AGED; DISEASE COURSE; MIDDLE AGED; ONSET AGE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PSYCHOLOGICAL ASPECT;

AGE OF ONSET; AGED; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE PROGRESSION; HUMANS; MIDDLE AGED; NOOTROPIC AGENTS;

EID: 78649675653     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: 10.2515/therapie/2010039     Document Type: Article

References (10)

1. CHMP 2008. Guideline on medicinal products for the treatment of Alzheimer's disease and other dementias, http : //www. emea. europa. eu/ pdfs/human/ewp/\Tl\OS5395en.pdf
2. Lathia CD, Amakye D, Dai W. et al. State of the art. The value, qualification, and regulatory use of surrogate end points in drug development. Clinical Pharmacology & Therapeutics 2009; 86 (1): 32-43
3. Snider BJ, Fagan AM, Roe C, et al. Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. Arch Neurol 2009: 66(5): 638-45
4. Jack CR. Bernstein MA, Borowski BJ, et al. Update on the magnetic resonance imaging core of the Alzheimer's disease neuroimaging initiative. Alzheimer's & Dementia 2010; 6(3): 212-20
5. Jagust WJ, Bandy D, Chen K, et al. The Alzheimer's disease neuroimaging initiative positron emission tomography core. Alzheimer's & Dementia 2010: 6(3): 221-9
6. Walhovd KB. Fjell AM, Brewer J, et al. Combining MR imaging, positronemission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease. American Journal of Neuroradiology 2010; 31: 347-54
7. Van der Vlies AE. Verwey NA, Bouwman FH. et al. CSF biomarkers in relationship to cognitive profiles in Alzheimer Disease SYMBOL. Neurology 2009:72(12): 1056-61
8. Fagan AM, Mintun MA, Shah AR, et al. Cerebrospinal fluid tau and ptaulSl increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of AD. EMBO Molecular Medicine 2009; 1(8-9): 371-80
9. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet 2007; 6: 734-46
10. Vellas B. Andrieu S, Aisen P. et al. for the Oxford Task Force Group. Biomarkers for Alzheimer's disease therapeutic trials: The Oxford Task Force. Forthcoming